Catalent Company profile
Catalent Pharma is the US number one health products and solutions provider. The company specialises in biologics, pre-formulation and formulation and runs its own optoform technology. Catalent Pharma prides itself on 1,300 patents and 7,000 products currently in market. The company's operations stretch across Asia Pacific, Europe, Latin America, and North America, covering more than 100 global markets.
Since 2014, Catalent stocks have been traded on the New York Stock Exchange (NYSE) under the CTLT ticker. The company is featured in the Top 50 pharma and Top 50 biotech companies lists. As of May 2018, the Catalent market cap reached 5.348B.
Browse the latest Catalent share price data and tap into the pharma industry at Capital.com.